Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Luis Felipe Falla Zuñiga Armando Sardi Mary Caitlin King Mary Caitlin King Philipp Barakat Carol Nieroda Teresa P Diaz-Montes Vadim Gushchin

Published in: Pleura and peritoneum (2023)

In patients with PM from rare ovarian malignancies, CRS/HIPEC is feasible and has an acceptable safety profile. Longer follow-up and multicenter trials are needed.

Keyphrases

minimally invasive
particulate matter
coronary artery bypass
air pollution
heavy metals
locally advanced
cross sectional
polycyclic aromatic hydrocarbons
squamous cell carcinoma
surgical site infection
risk assessment
clinical trial
coronary artery disease
newly diagnosed